Network-Level Mechanisms for Preclinical Alzheimer's Disease Development

NCT03461861 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

26

Enrollment

OTHER

Sponsor class

Conditions

APOE 4

Interventions

DRUG: AGB101 220 mg
OTHER: Placebo

Sponsor

Medical College of Wisconsin

Collaborators

[object Object]